KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Other Accumulated Expenses (2016 - 2025)

Exact Sciences (EXAS) has disclosed Other Accumulated Expenses for 15 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 59.7% to $15.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.2 million, a 59.7% decrease, with the full-year FY2025 number at $15.2 million, down 59.7% from a year prior.
  • Other Accumulated Expenses was $15.2 million for Q4 2025 at Exact Sciences, up from $14.3 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $50.6 million in Q1 2021 to a low of $8.8 million in Q1 2023.
  • A 5-year average of $26.9 million and a median of $29.5 million in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 786.78% in 2021, then plummeted 69.56% in 2023.
  • Exact Sciences' Other Accumulated Expenses stood at $31.0 million in 2021, then crashed by 66.91% to $10.2 million in 2022, then soared by 44.63% to $14.8 million in 2023, then surged by 154.77% to $37.8 million in 2024, then plummeted by 59.7% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Other Accumulated Expenses are $15.2 million (Q4 2025), $14.3 million (Q3 2025), and $16.1 million (Q2 2025).